eXoZymes is redefining how complex molecules are discovered, manufactured, and commercialized. Its AI-enhanced, cell-free biomanufacturing platform turns rare, unscalable, or economically inaccessible chemistry into predictable, high-purity production. By embedding manufacturability directly into discovery, eXoZymes collapses development timelines, lowers capital intensity, and unlocks multiple commercialization paths. The result is a scalable platform with durable IP, capital-light growth, and asymmetric upside across pharmaceutical, wellness, and industrial markets.

enzymes x AI = exozymes
Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into medicines and nutraceuticals. By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.